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Pluripotent Stem Cells
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ABSTRACT
We have developed a robust, Good Manufacturing Practice-compatible differentiation protocol ca-
pable of producing scalable quantities of red blood cells (RBCs) from human pluripotent stem cells
(hPSCs). However, translation of this protocol to the clinic has been compromised because the RBCs
produced are not fullymature; thus, they express embryonic and fetal, rather than adult globins, and
they do not enucleate efficiently. Based on previous studies, we predicted that activation of exoge-
nous HOXB4 would increase the production hematopoietic progenitor cells (HPCs) from hPSCs and
hypothesized that it might also promote the production of more mature, definitive RBCs. Using a
tamoxifen-inducible HOXB4-ERT2 expression system, we first demonstrated that activation of
HOXB4 does increase the production of HPCs from hPSCs as determined by colony-forming unit
culture activity and the presence of CD43+CD34+ progenitors. Activation of HOXB4 caused a mod-
est, but significant, increase in the proportion of immature CD235a+/CD71+ erythroid cells. How-
ever, this did not result in a significant increase in more mature CD235a+/CD712 cells. RBCs
produced in the presence of enhanced HOXB4 activity expressed embryonic («) and fetal (g)
but not adult (b) globins, and the proportion of enucleated cells was comparable to that of the
control cultures. We conclude that programming with the transcription factor HOXB4 increases
the production of hematopoietic progenitors and immature erythroid cells but does not resolve
the inherent challenges associated with the production of mature adult-like enucleated RBCs.
STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1–10
SIGNIFICANCE
As worldwide blood donations decrease and transfusable transmitted infections increase, intense
interest has ensued in deriving red blood cells (RBCs) in vitro from alternative sources such
as pluripotent stem cells. A translatable protocol was developed to generate RBCs; however,
these RBCs have an immature phenotype. It was hypothesized that the transcription factor
HOXB4 could enhance their production andmaturation. Although HOXB4 increased the produc-
tion of erythroid progenitors, it did not promote their maturation. Despite the remaining chal-
lenges, a robust system has been established to test other candidates and add to the knowledge
base in this field.
INTRODUCTION
Cell-based therapies such as bone marrow trans-
plantation and blood transfusion are used to treat
diseases of the hematopoietic system; however,
these procedures are completely reliant on a lim-
itedsupplyofdonor tissue.Thus,onegoalhasbeen
to produce therapeutic hematopoietic cells from a
bankable and limitless source of human embryonic
stem cells (hESCs) or induced pluripotent stem
cells (iPSCs) [1–3]. Many studies have been re-
ported on the production of hematopoietic pro-
genitors cells (HPCs) and mature hematopoietic
cells from ESCs and iPSCs; however, it has been
widely acknowledged that significant challenges
exist in this field. The differentiation protocols
that have been used to date are relatively ineffi-
cient, and it has proved particularly difficult to
produce the most potent hematopoietic stem
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cells (HSCs) capable of long-term reconstitution (LTR-HSCs) and
fully mature red blood cells (RBCs) that express adult b-globin
and enucleate [4–6].Most of the strategies used to produce ery-
throid cells have required the use of stromal cell feeder layers
and/or ill-defined serum, whichwould present significant safety
issues in clinical translation [7–11]. Feeder-free hematopoietic
differentiation strategies have been developed, but many of
these required lengthy embryoid body stages that have proved
difficult to control and replicate effectively [8, 12, 13]. The pro-
duction of fully mature adult-like erythroid cells that undergo
appropriate globin switching has been particularly challenging,
with most studies detecting embryonic (z, «) and fetal (g) but
not adult (b) globin [8, 11, 14]. Although some studies have re-
ported the production of some enucleated cells, none of these
have demonstrated a convincing and robust degree of enucle-
ation in pluripotent stem cell-derived RBCs [9, 12].
The first wave of erythropoiesis in vivo occurs in the yolk
sac and is responsible for the production of primitive nucleated
erythrocytes. A second wave initially arises in the aorta-gonad-
mesonephros region, where the first definitive HSCs arise that
are capable of long-termmultilineage reconstitution and produc-
tion of adult nucleated erythrocytes [15]. We hypothesized that
the limited production of nucleated erythrocytes that can be
achieved from pluripotent stem cells in vitro might reflect the
“primitive” state of the progenitors produced in this system. This
is supported by the finding that the production of LTR-HSCs in
vitro from pluripotent stem cells capable of multilineage long-
term reconstitution has proved particularly difficult to achieve.
We reasoned that HOXB4 might be a transcription factor that
could program hPSC-derived hematopoietic cells to a more “de-
finitive” phenotype, because it has been shown to confer long-
term reconstitution ability on primitive yolk sac cells and mouse
ESCs [16–18]. Furthermore, our studies of themurine ESC system
have demonstrated that HOXB4 could promote a paracrine ef-
fect; thus, its actions could mimic the action of stromal cell co-
culture [19–21]. The effects of exogenous HOXB4 on human
ESCs has been less clear, with contradictory outcomes likely re-
lated to the range of the differentiation protocols used and the
different expression strategies used, leading to variations in the
level and timing of expression [19]. In thepresent study,weused
a controllable HOXB4 expression system in which we could ac-
tivate HOXB4 at different time points in a well-defined differen-
tiation protocol.
We have developed a stepwise, serum- and feeder-free clin-
ical grade protocol for both the growth and the maintenance of
hESCs and hiPSCs and their subsequent expansion and differenti-
ation into erythroid cells [22]. We tracked the emergence of HPCs
using colony-forming unit culture (CFU-C) and flow cytometry and
then tested the effects of tamoxifen-inducible expression of
HOXB4 in this defined and robust hematopoietic differentiation
protocol. In keeping with the results from murine studies, we
found that enforced expression of HOXB4 resulted in a specific in-
crease in the production of multilineage HPCs. We also noted a
modest increase in the production of immature erythroid cells,
but, overall, no significant effect was found for their subsequent
maturation. The erythroid cells that were produced in the pres-
ence of HOXB4 failed to undergo efficient enucleation and
expressed embryonic («) and fetal (g), but not adult (b), globin.
Thus, enforced expression of HOXB4 did not overcome the major
difficulty in the production of mature enucleated cells required
for transfusion.
MATERIALS AND METHODS
Maintenance and Differentiation of hESCs
Human pluripotent stem cell lines, including H1 [23] and Runx1C-
GFP [24], were routinely maintained in StemPro hESC serum-free
medium on CELLstart matrix (Thermo Fisher Scientific Life Sciences,
Waltham, MA, http://www.thermofisher.com) with the addition
of basic fibroblast growth factor (bFGF) 20 ng/ml (PHG0021;
Thermo Fisher Scientific Life Sciences), and passaged (1:4) when
70%–80% confluent, using StemPro EZPassage tools (Thermo
Fisher Scientific Life Sciences). Differentiation was performed in
a stepwise, serum- and feeder-free protocol, as described [22].
In brief, one confluent well of human ESCswas cut and transferred
to two wells (six-well plates; cell repellant surface; catalog no.
657970; Greiner Bio-One, Kremsmu¨nster, Austria, http://www.
greinerbioone.com) and then cultured in 3 ml per well of Stemline
II Hematopoietic Stem Cell ExpansionMedium (catalog no. S0192;
Sigma-Aldrich, St. Louis, MO, http://www.sigmaaldrich.com) with
the addition of bone morphogenetic protein 4 (BMP4) 10 ng/ml
(catalog no. 314-BP-010; R&D Systems, Minneapolis, MN, http://
wwwrndsystems.com), vascular endothelial growth factor (VEGF)
10 ng/ml (catalog no. 293-VE010; R&D Systems), Wnt3a 10 ng/ml
(catalogno.5036-WN010;R&DSystems), activinA5ng/ml (catalog
no. 338-AC010; R&D Systems), and glycogen synthase kinase
(GSK-3b) inhibitorVIII2mM(catalogno.A014418;MerckMillipore,
Billerica, MA, http://www.merckmillipore.com). EBs formed spon-
taneously, and after 2 days, the following cytokines were added in
500 ml of Stemline II per well: BMP4 20 ng/ml, VEGF 30 ng/ml,
Wnt3a 10 ng/ml, activin A 5 ng/ml, fibroblast growth factor-a
(FGF-a) 10 ng/ml (catalog no. PHG0014; Thermo Fisher Scientific
Life Sciences), stem cell factor (SCF) 20 ng/ml (catalog no. PHC
2111; Thermo Fisher Scientific Life Sciences), and GSK inhibitor VIII
2 mM. EBs were disaggregated on day 3 with 0.5 ml per well
StemPro Accutase Cell Dissociation Reagent for 3 minutes at 37°C,
before gently pipetting 10 times and adding prewarmed medium.
After centrifugation, thecellswerereplatedat23105cellsperwell
(six-well plates; Corning, Corning, NY, http://www.corning.com)
in 3 ml of Stemline II, with the addition of BMP4 20 ng/ml, VEGF
30 ng/ml, FGF-a 10 ng/ml, SCF 30 ng/ml, insulin-like growth factor
2 (IGF2) 10 ng/ml (catalog no. 292-G2; R&D Systems), thrombo-
poietin (TPO) 10 ng/ml (catalog no. 288-TPN-25; R&D Systems),
heparin 5 mg/ml (catalog no. H3149; Sigma-Aldrich), and isobutyl-
methylxanthine (IBMX) 100mM(catalog no. I5879; Sigma-Aldrich).
On day 7, the floating cells and medium were carefully removed
and centrifuged before replating all the cells back into the same
dishes (containing any adherent cells) in 3 ml of fresh Stemline II
medium containing BMP4 20 ng/ml, VEGF 30 ng/ml, FGF-a
10 ng/ml, SCF 30 ng/ml, IGF2 10 ng/ml, TPO 10 ng/ml, heparin
2.5mg/ml, and IBMX 100mM. On day 9, the same day-7 cytokines
were topped up in 500ml of Stemline II per well. On day 10, all the
cells were aspirated from the well, centrifuged, and placed in
500 mΜ Accutase solution 37°C for 3 minutes, and 3 3 105 cells
were replated per well in IBITmedium (240ml of Iscove Basal Me-
dium; catalog no. FG-0465; Biochrome, Merck Millipore), 1% bo-
vine serum albumin (BSA; catalog no. G10008-01; Thermo Fisher
Scientific Life Sciences), 10 mg/ml insulin (catalog no. I9278;
Sigma-Aldrich), 0.2 mg/ml transferrin (catalog no. T0665; Sigma-
Aldrich), and 500 ml b-mercaptoethanol (catalog 31550-010;
Thermo Fisher Scientific Life Sciences), with the addition of hy-
drocortisone 10 mM, SCF 50 ng/ml, FMS-like tyrosine kinase
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receptor 3 ligand (Flt3L) 16.7 ng/ml (catalog no. 300-19; Pepro-
Tech, RockyHills, NJ, http://www.peprotech.com), BMP4 6.7 ng/ml,
interleukin (IL)-36.7ng/ml (catalog213-13;PeproTech), IL-116.7ng/
ml (catalog no. 200-11; PeproTech), erythropoietin (EPO) 3 U/ml
(catalog no. 287-TC-500; R&D Systems), and IBMX 100 mM. Every
2 days, the cytokines were topped up in a volume of 500 ml per
well. On day 17, the cells were centrifuged and counted, and 1 3
106 cells were plated per well in IBIT with the addition of hydrocor-
tisone 10 mM, SCF 20 ng/ml, IGF1 20 ng/ml (catalog no. 100-11;
PeproTech), IL-3 6.7 ng/ml, IL-11 6.7 ng/ml, and EPO 3 U/ml. The
cytokines were replenished at the same concentrations every 2
days in a volume of 500 ml per well.
Flow Cytometry
The cells were harvested, and 2 3 105 cells were placed in
aliquots in phosphate-buffered saline (PBS) containing 1%
BSA (PBS/BSA) and centrifuged (200g) for 5 minutes. Anti-
bodies were added directly to cell pellets that were then resus-
pended to a final volume of 100 ml, incubated for 30 minutes
on ice, washed in 5 ml PBS/BSA, and resuspended in 300 ml.
The samples were analyzed using an LSRFortessa (BD Biosci-
ences, Franklin Lakes, NJ, http://www.bdbiosciences.com) us-
ing FACSDiva acquisition (BD Biosciences) and FlowJo analysis
software (FlowJo, Ashland, OR, http://www.flowjo.com), or
sorted on a FACSARIA (BD Biosciences). Anti-human antibodies
included CD71-FITC (catalog no. 11-0719; eBioscience, San
Diego, CA, http://www.ebioscience.com), CD43-APC (catalog no. 17-
0439-42; eBioscience), glycophorinA (M) (CD235a), efluor450 (catalog
no.48-9884;eBioscience),CD34-PE(catalogno.12-0349;eBioscience),
CD41a-FITC(BDBiosciences),CD45-V450(BDBiosciences),andCD144-
PE (Beckman Coulter, Brea, CA, http://www.beckmancoulter.com).
Mouse IgG1 APC isotype control (catalog no. 17-4714-81; eBio-
science) and mouse IgG1 PE isotype control (catalog no. 12-
4714-81; eBioscience) were used (supplemental online Fig. 2).
CFU-C Assay
Single cells (53 103 or 104) were plated into 1.5 ml of Methocult
medium containing SCF, granulocyte colony-stimulating factor
(CSF), granulocyte macrophage CSF, IL-3, IL-6, and erythropoietin
(StemCell Technologies, Inc., Vancouver, BC, Canada, http://www.
stemcell.com) in 35-mm-dish low-attachment plates (Greiner
Bio-One), incubated at 37°C in a humid chamber, and scored
for hematopoietic colony formation after 12–15 days.
Magnetically Activated Cell Sorting
Magnetically activated cell sorting (MACS) was performed
according to the manufacturer’s instructions (Miltenyi Biotec,
Bergisch Gladbach, Germany, http://www.miltenyibiotec.com).
In brief, the cells were resuspended in PBS containing 2 mM
EDTA, incubated in FC blocking agent for 10 minutes at room
Figure1. Monitoringhematopoietic progenitor production throughout thedifferentiationprotocol. Representative flowcytometry analysis of
cells from days 0 to 24 of the differentiation protocol using antibodies against CD34 and CD43 (A) and the quantification of the percentage
positive (B) was performed from at least three independent experiments. Absolute cell numbers of the differentiation represented in (A)
are shown for days 3 and 10 (C). Representative colonies generated from day 7 (Di–Div) and day 10 (Dv–Dviii) cells are shown, CFU-C activity
having been assessed bymethylcellulose assays on days 7 and 10 (E). These data represent three independent experiments, andbars indicate the
SEM. Flow cytometry analysis to assess the expression of Runx1C-GFP in the CD34/CD43 double-positive cell population; Runx1C-GFP+ cells are
shown in green and Runx1C-GFP2 cells in red (F). Original magnification360. Abbreviations: CFU, colony-forming unit; G, granulocyte; GFP,
green fluorescent protein; GM, granulocyte macrophage; M, macrophage; Q, quartile.
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temperature, combined with microbead-labeled antibody
(Miltenyi Biotec; CD43:130-091-333 or CD34:130-046-702) for
20 minutes at 4°C, then washed and resuspended in PBS/EDTA.
Labeled cells were then applied in 250-ml aliquots to the MACS
column, left to stand in the magnet for 5 minutes, and then
washed three times with 0.5ml PBS/EDTA. The cells were released
from the column according to the manufacturer’s instruction, and
the purity of sorted cells was assessed by flow cytometry.
hESC Transfection
H1 hESCs were fed with fresh StemPro medium containing 20 ng/ml
bFGF (R&D Systems) and 10mMROCK inhibitor (catalog no. Y-27632;
Calbiochem, EMDMillipore, Billerica, MA, http://www.emdmillipore.
com) at least 1 hour before electroporation, as described previously
[25]. Single cell suspensions were generated using Accutase, then
thecellswerewashedandresuspended inStemPromedium(107cells
per 0.5 ml) with 30 mg of linearized pCAG-HOXB4ERT2-IRES-PURO
vector [20]. Thecellswereelectroporated (GenePulserXcell: 320V,
250 mFd; Bio-Rad, Hercules, CA, http://www.bio-rad.com), plated
on CELLstart matrix (Thermo Fisher Scientific Life Sciences) in
StemPro medium containing 20 ng/ml bFGF (R&D Systems) and
10mMROCK inhibitor (catalogno. Y-27632; Calbiochem). Resistant
colonies were selected in 0.6 mg/ml puromycin for 10 days, then
singlecolonieswerepicked,expanded,andscreenedforexpression
of HOXB4 by Western blot (supplemental online Fig. 1).
High-Performance Liquid Chromatography
High-performance liquid chromatography (HPLC) globin chain sepa-
ration was performed using a protocol modified from Lapillonne
Figure2. CFU-CactivitywasenrichedwithintheCD34hiCD43+cellpopulation.CD34+cells fromday7cultures (A)andCD43+cells fromday10cultures (C)
weresortedusingmagnetically activatedcell sortingenrichmentandreanalyzedby flowcytometry toassesspurity (unsorted [red], enrichedpositivecells
[blue], and flow-through low/negative cells [green]).Hematopoietic activitywasquantifiedbyplating thesecell populations inCFU-Cassays (B,D). Day10
cultureswerestainedforbothCD34andCD43 (E)andCD43+/CD342,CD43+/CD34+double-positive,andCD432CD342double-negativecellswereplatedin
CFU-C assays to quantify their hematopoietic activity (F). Abbreviations: BFU-E, burst-forming unit erythroid; CFU, colony-forming unit; GM, granulocyte
macrophage; M, monocyte; Max, maximum; MIX, mixed; NEG, negative; POS, positive; Q, quartile.
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et al. [9]. Erythroid cells werewashed three times in PBS, lysed in 50
ml of 0.1% trifluoroacetic acid (TFA) in water. The cells were then
centrifuged at 13,000g at 4°C for 10 minutes, and the supernatant
was collected for HPLC analysis. Globin chain separation was
performed by injecting 10 ml of the supernatant onto a 1.0 3
250-mm C4 column (Phenomenex, Macclesfield, U.K., http://
www.phenomenex.com) with a 42%–56% linear gradient between
mixtures of 0.1% TFA in water and 0.1% TFA in acetonitrile at a flow
rate of 0.05 ml per minute for 50minutes on a HPLC Ultimate 3000
system (Dionex, Thermo Fisher Scientific Life Sciences). The column
temperature was fixed at 50°C during analysis, and the UV detector
was set at 220 nm. Lysates from adult peripheral blood and fetal
liver were used as positive controls. The elution times of the peaks
generatedwere comparedwith thoseof the control peaks for iden-
tification. The area under the curve was used to calculate the pro-
portion of each globin peak from each sample.
RESULTS
Monitoring Hematopoietic Progenitor Production
We monitored the production of HPCs throughout the differen-
tiation protocol by flow cytometry and CFU-C assays (Fig. 1).
The proportion of cells expressing CD34 and CD43 peaked be-
tween day 6 and 10 (Fig. 1A, B), and the appearance of cells car-
rying these HPC markers coincided with the presence of CFU-C
colonies (Fig. 1E). Most CFU-C generated from the day 7 cells
were small, primitive-like colonies (Fig. 1Di–3Div) with larger,
more robust colonies produced by cells in the day 10 cultures
(Fig. 1Dv–1Dviii). The absolute numbers of the CD34+ and
CD43+ populations within the cultures at days 3 and 10were cal-
culated. The most abundant population at day 10 was the
CD34+/CD43+ double-positive population (Fig. 1C). To further
characterize the HPCs generated in our differentiation protocol,
we used the RUNX1CGFP/w hESC line carrying a green fluorescent
protein (GFP) reporter under the control of the endogenous
Runx1C promoter [24], which is considered to be a marker of
definitive hematopoietic stem cells [26]. Most of the double-
positive, CD34+CD43+ cells at day 10 also expressed Runx1C-
GFP, confirming their definitive progenitor-like phenotype
(Fig. 1F). To determine which cell population contained the he-
matopoietic activity, we used MACS to differentiate ESCs at day
7 according to CD34 expression (Fig. 2A) and at day 10 according
to CD43 expression (Fig. 2C) and then analyzed the enriched
populations for hematopoietic colony activity (Fig. 2B, 2D).
Figure 3. Activation of HOXB4 enhanced the production of hematopoietic progenitors. Tamoxifen (labeled + or2) was added to cultures to
activate HOXB4 in H1 human embryonic stem cells (hESCs) expressing HOXB4-ERT2 (labeled HOXB4) or parental H1 hESCs (labeled control) be-
tween days 0 and 10 (A) and then assessed for CFU-C activity (B) and expression of hematopoietic progenitor markers, CD34 and CD43, by flow
cytometry (C, D). Data were generated from four independent experiments, with error bars representing SEM. p, p = .03; pp, p = .04. Abbre-
viations: 4OHT, tamoxifen; BFU-E, burst-forming unit erythroid; BMP4, bonemorphogenetic protein 4; C, cell; CFU, colony-forming unit; FGF a,
fibroblast growth factor-a; GM,granulocytemacrophage;GSK, glycogen synthasekinase; IBMX, isobutylmethylxanthine; IGF2, insulin-likegrowth
factor 2; M, macrophage; Q, quartile; SCF, stem cell factor; TPO, thrombopoietin; VEGF, vascular endothelial growth factor.
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The maximum number of CFU-Cs was found within the CD34hi
population at day 7 and CD43+ population at day 10. Further
analyses of the fluorescence activated cell-sorted day 10 cells
demonstrated that CFU-C activity was contained within the
CD43+CD34+ and the CD43+CD342 (Fig. 2E, 2F).
Enforced Expression of HOXB4
HOXB4hasbeenwidely reported toenhance theproductionofhema-
topoietic cells frommurine ESCs; however, its effect on the differen-
tiation of hESCs is less clear. The variable findings from hESC studies
likely result from the variety of differentiation strategies and the dif-
ferent systems used to express HOXB4, resulting in differing expres-
sion levels [19]. Based on our previous studies, we hypothesized
that activation of exogenous HOXB4 would increase the production
of HPC during the differentiation process [20] and might also act to
promoteamore “definitive-likeprogenitor” capableofdifferentiating
into mature adult-like RBCs that could express adult globins and
enucleate efficiently. To assess the effects of HOXB4 in our defined
differentiation protocol, we transfected H1 hESCs with a
tamoxifen-inducible HOXB4-ERT2 transgene under the control
of the CAG promoter, as previously described [20].We have pre-
viously confirmed and reported that the HOXB4-ERT2 fusion pro-
tein can localize to the nucleus with the addition of tamoxifen
and that it is functional in this context by demonstrating the in-
duced expression of the HOXB4 target gene, Frzb, with the ad-
dition of tamoxifen [20]. The expression of the HOXB4-ERT2
protein and the hematopoietic differentiation potential of
hESCs carrying this transgene were confirmed by Western
blotting and CFU-C assays (supplemental online Fig. 1).
We first tested the effects of HOXB4 activation on the pro-
duction of HPCs in differentiating hESCs carrying this transgene
Figure 4. Activation of HOXB4 resulted in amodest increase in the proportion of immature CD235a+/CD71+ erythroid cells. HOXB4was activated
with4OHTfromdays10to24 (A). ProductionoferythroidcellswasmonitoredbyexpressionofCD235aandCD71byflowcytometryatday24 (B–D).
Dataweregenerated from four independent experimentswitherror bars representing the SEM.p,p = .05.Abbreviations: 4OHT, tamoxifen; BMP4,
bonemorphogenetic protein 4; C, cell; CFU, colony-forming unit; EPO, erythropoietin; FGF a, fibroblast growth factor-a; FLT3L, FMS-like tyrosine
kinase receptor 3 ligand; GSK, glycogen synthase kinase; IBMX, isobutylmethylxanthine; IGF1, IGF2, insulin-like growth factor 1, 2; IL, interleukin; Q,
quartile; SCF, stem cell factor; TPO, thrombopoietin; VEGF, vascular endothelial growth factor.
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in the presence and absence of tamoxifen for 10 days by CFU-C
assays and flow cytometry (Fig. 3). We observed a significant
increase in the number of CFU-Mix and CFU-granulocytemacro-
phage colonies in the presence of tamoxifen in cells expressing
the HOXB4-ERT2 transgene but not in control H1 ESCs (Fig. 3B).
No significant difference was found in the number of CFU-
macrophage (CFU-M) or burst-forming units-erythroid (BFU-E)
in the presence and absence of tamoxifen in either cell line,
indicating that enforced expression of HOXB4 preferentially
enhanced the production, proliferation, or survival of multipo-
tent HPCs. Consistent with the CFU-C data, the proportion of
CD34+CD43+ double-positive cells was increased when HOXB4
was activated by tamoxifen (Fig. 3C, 3D). The overall proportion
of cells expressing CD43 did not change when HOXB4 was acti-
vated; thus, the increase in double-positive CD34+/CD43+ cells
resulted from an increase in the number of cells expressing
CD34 (Fig. 3C).
To assess the effects of enforced HOXB4 expression on RBC
maturation, we generated HPCs in the absence of tamoxifen
and then added tamoxifen to the later stages of differentiation
(days 10–24; Fig. 4A). We observed no effect of tamoxifen on
the overall proportion of erythroid cells that expressed CD235a
at day 24, but we noted differences in the proportion of those
CD235a+ cells that coexpressed CD71 (Fig. 4B–4D). The CD71
marker is lost as erythroid cells mature, and we noted that
the proportion of the less mature CD235a+/CD71+ cells was sig-
nificantly increased with HOXB4 activation (Fig. 4C). However,
no significant difference was found in the proportion of the
more mature cells (Fig. 4D). Hemoglobinized cells were ob-
served in cultures in both the presence and the absence of ta-
moxifen, and the globin profile of these cell populations was
analyzed by HPLC at day 24 (Fig. 5A, 5B). b-globin was detected
in control fetal and adult blood samples, but hESC-derived RBCs
generated predominantly embryonic («) and fetal (ga and gg)
Figure5. HOXB4 activation had no significant effect on thematuration of pluripotent stem cell-derived erythroid cells. High-performance
liquid chromatography analysis of cell lysates generated at day 24 of the differentiation protocol from control (H1) and HOXB4-activated
cells [in the presence (+T) and absence (2T) of tamoxifen] (A). The amount of the different globins detected as a proportion of the total
globin content was calculated in six independent experiments (B). Adult peripheral blood and fetal blood were included for comparison.
Enucleation of control andHOXB4-expressing human embryonic stem cells (hESCs) in the presence (+T) and absence (2T) of tamoxifenwas
assessed by flow cytometry using the nuclear SYTO Red stain and the erythroid marker, CD235a (C). A representative histogram of SYTO
Red staining of control enucleated peripheral blood samples (blue), nucleated mononuclear cells (green), and hESCs after HOXB4 acti-
vation (orange) are shown together with the unstained control hESCs (D). Abbreviation: HuESC, human embryonic stem cell.
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globins. Activation of HOXB4 either from days 10 to 24 (data
shown) or from days 0 to 24 (data not shown) did not alter this
profile, indicating that it had no effect on maturation of the ery-
throid cells. We predict that altering the activation time period
(e.g., from days 10 to 17 or from days 17 to 24) would have a
similar negative effect; however, we could not exclude the pos-
sibility that different effects might be observed. We also noted
that activation of HOXB4 did not alter the efficiency of enucle-
ationof hESC-derivedRBCs as assessedby stainingwith the SYTO
red fluorescent nucleic acid stain (Fig. 5C) and compared directly
with the white blood cell and red blood cell fractions from pe-
ripheral blood (Fig. 5D). Globin profiles and enucleation rates
were also analyzed in cultures that were activated with HOXB4
throughout the differentiation protocol (i.e., from day 0 to 24),
with similar results (data not shown).
Because one of the aims of the present study was to deter-
mine whether HOXB4 activation could enhance the number of
RBCs that could be generated, we also assessed the effects
of HOXB4 on cell expansion throughout the culture period.
A 10,000-fold expansion occurred in cell numbers during the
24-day culture period in the control cells and in the hESCs carrying
theHOXB4-ERT2 transgene in the absenceof tamoxifen.However,
a significant reduction in expansion was observed with HOXB4
activation (Fig. 6). Previous studies have indicated that HOXB4
enhances the proliferation of HPCs ex vivo without significant
effects on their differentiation potential [27, 28]. However, we
have demonstrated that this cannot be applied to more commit-
ted progenitors.
DISCUSSION
The development of strategies to produce transfusion-competent
RBCs from a limitless supply of human PSCs would have an enor-
mous impact on this widely used therapy. However, to date,
most RBCs produced in vitro from this source have had an imma-
ture phenotype, characterized by an embryonic or fetal globin
profile (or both) and nuclear retention [1]. Although some evi-
dence has shown that iPSC-derived RBCs can undergo terminal
differentiation when transplanted in vivo, the nucleated state
would preclude the clinical use of these cells [29]. In contrast,
RBCs differentiated in vitro from adult, fetal liver, or umbilical
cord blood cells enucleated efficiently, demonstrating that it
is possible to create a microenvironment in vitro that will sup-
port the enucleation process [30, 31]. Adult stem cell-derived
enucleated RBCs have been used in a proof-of-principal clinical
transfusion study [31]. Although coculture with fetal liver stro-
mal cells can improve the enucleation efficiency of PSC-derived
cells, the proportion of enucleated cells remains prohibitively
low, and this type of strategy could not be translated into
the clinic. A recent study that analyzed the molecular profile
of enucleating cells derived from hESCs identified a microRNA
(microRNA-30a) as a potential regulator of the enucleation pro-
cess, demonstrating that it is also possible to modulate the pro-
cess by altering the intrinsic genetic environment [32].
From our previous findings that enhanced expression of
HOXB4 could exert a paracrine effect in differentiating ESCs
[20] and that combining coculture with HOXB4 expression did
not have an additive effect [21], we sought to test the hypothesis
that enhanced expression of this transcription factor could create
a microenvironment that would allow for the production of
hematopoietic progenitors capable of differentiating into ma-
ture erythroid cells. We used a defined, feeder-free culture sys-
tem designed for the production and expansion of erythroid
cells [22].
Production of Hematopoietic Progenitors
We first monitored the production and phenotype of hemato-
poietic progenitors produced in this defined stepwise proto-
col. More than 60% of cells expressed HPC markers between
days 8 and 10, and the time course of CD43+CD34+ cell produc-
tion correlated with the production of CFU-C clonogenic
progenitors. At this stage, CD43+CD34+ cells predominantly
expressed the Runx1C-GFP reporter, supporting their progenitor-
like phenotype. The phenotype and potential of PSC-derived
hematopoietic progenitors is consistent with that described
for differentiating hiPSCs using the OP9 coculture system
[33–35]; thus, our robust stepwise protocol is an appropriate
system to assess the effects of specific transcription factors
on the differentiation process.
Enhanced Expression of HOXB4
We hypothesized that the deficiency in erythroid matura-
tion could result from the primitive nature of hematopoietic
Figure 6. Cell expansion data for H1 human embryonic stem cells
(control) (B) and HOXB4-ERT2-expressing human embryonic stem
cells (HOXB4) (A) in the presence (+) and absence (2) of tamoxifen
for 24 days. Data are expressed as fold expansion comparedwith the
number of cells at day 3 and represent the mean of six independent
experiments (6 SE).
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progenitors that are generated in vitro. We considered that
HOXB4 might be a transcription factor that could program
hPSC-derived hematopoietic cells to a more definitive pheno-
type, because it had been shown to confer long-term reconsti-
tution ability on primitive yolk sac cells and mouse ESCs [16,
17]. The results described in previous studies using human
PSCs were contradictory, likely because of differences in the
expression strategies and differentiation protocols that were
used [19]. To resolve the discrepancies in the published re-
ports, we used a defined differentiation protocol without
feeder cells and an inducible expression system in which we
could control the timing of the expression of HOXB4. We have
demonstrated that enforced expression of HOXB4 increases
the production of multilineage hematopoietic progenitors
but has no significant effect on the production and maturation
of RBCs. The erythroid progenitors that were produced in the
presence of HOXB4 failed to undergo efficient enucleation and
expressed embryonic («) and fetal (g) but not adult (b) globin.
In addition, we observed a detrimental effect of HOXB4 activity
on cell expansion, negating any small increases in cell popula-
tions seen by inducing HOXB4.
CONCLUSION
The differentiation system we have defined in the present
study generates hematopoietic progenitors and is robust
enough to test the effects of the numerous transcription fac-
tors shown to program hematopoietic development [36–38].
We have demonstrated that HOXB4 increased the proportion
of hematopoietic progenitor production. However, enhanced
activity of this transcription factor did not promote red blood
cell maturation.
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